Oncology Clinical Trial Execs to Increase Decentralization,
Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months...
Source: globenewswire.com
Page 6 - Science 37 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Science 37. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Science 37 Today - Breaking & Trending Today
Science 37® to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...
Source: globenewswire.com
Science 37 (NASDAQ:SNCE) Lowered to Hold at Zacks Investment Research
Science 37 (NASDAQ:SNCE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Science 37 Inc. provides operating system for agile clinical trials. Science 37 Inc., formerly known as LifeSci Acquisition II Corp., is based in […]
Source: etfdailynews.com
Science 37® to Present at the William Blair 42nd Annual
RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™,...
Source: globenewswire.com
Critical Review: Science 37 (NASDAQ:SNCE) & iSpecimen (NASDAQ:ISPC)
Science 37 (NASDAQ:SNCE – Get Rating) and iSpecimen (NASDAQ:ISPC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation. Valuation & Earnings This table compares Science 37 and iSpecimen’s […]
Source: etfdailynews.com